ХУАН Сяохун (US),ЖАССОН Мартин (FR),МАРК Ванесса (FR),РЕЙДИН Аллен (US)
申请号：
RU2014118741/15
公开号：
RU2014118741A
申请日:
2012.10.10
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating rheumatoid arthritis in a patient previously treated with methotrexate, leflunomide, sulfasalazine and / or hydroxychloroquine, comprising administering to the patient an effective amount of sarilumab (SAR153191), where sarilumab is administered at a dose of 150 mg once every two weeks or 200 mg once every two weeks .2. The method of claim 1, wherein the patient has previously been ineffectively treated for rheumatoid arthritis by administering methotrexate, leflunomide, sulfasalazine and / or hydroxychloroquine. The method of claim 2, wherein methotrexate, leflunomide, sulfasalazine and / or hydroxychloroquine are administered together with sarilumab. The method of claim 3, wherein sarilumab and methotrexate are administered together. The method of claim 4, wherein methotrexate is administered at a dose of 6 to 25 mg per week. The method of claim 1, wherein sarilumab is administered at a dose of 150 mg once every two weeks. The method of claim 1, wherein sarilumab is administered at a dose of 200 mg once every two weeks. The method according to claim 1, wherein the patient achieves a 20% improvement according to the criteria of the underlying disease of the American College of Rheumatology after 12 weeks of treatment. The method of claim 1, wherein the patient achieves a 50% improvement according to the criteria for the underlying disease of the American College of Rheumatology after 12 weeks of treatment. The method of claim 1, wherein the patient achieves a 70% improvement according to the criteria for the underlying disease of the American College of Rheumatology after 12 weeks of treatment. The method of claim 1, wherein the patient has previously been ineffectively treated for rheumatoid arthritis by administering a TNF-α.12 antagonist. The method of claim 11, wherein the patient has been treated with an anti-TNF-α antagonist for at least 3 months in the last 2 years or the patient does not tolerate at least one TNF-α antagonist. The me
